For example, pharmacological PI3K inhibition rescues inducible arteriovenous malformations in the context of an inducible animal model for a recurrent transforming growth factor-b (TGF-b)/bone morphogenetic protein (BMP) signaling pathway gene mutation, known to cause hereditary hemorrhagic telangiecstasia (Ola et al., 2016). The gene discussed is TGFB1; the disease is arteriovenous hemangioma/malformation.